RESUMO
Dipropylacetamide (DEPAMIDE) was administered to 60 patients with bipolar manic-depressive psychoses. The dosage was 900 mg per day, administered orally. In 5 (8%) of the patients gastrointestinal disorders were observed. Administration of lithium carbonate results in undesirable side-effects in 50% of the cases. Our clinical experience shows dipropylacetamide to have a considerably slighter toxic effect on the human organism than lithium carbonate. We regard Dipropylacetamide (DEPAMIDE) as a valuable and significant addition in the prophylaxis of affective disorders, notably bipolar manic-depressive psychoses.
Assuntos
Anticonvulsivantes/uso terapêutico , Transtorno Bipolar/prevenção & controle , Ácido Valproico/uso terapêutico , Humanos , Ácido Valproico/análogos & derivadosAssuntos
Piracetam/uso terapêutico , Psicoses Alcoólicas/tratamento farmacológico , Pirrolidinonas/uso terapêutico , Adulto , Ensaios Clínicos como Assunto , Método Duplo-Cego , Humanos , Masculino , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica , Psicoses Alcoólicas/psicologia , Distribuição AleatóriaAssuntos
Lítio/sangue , Adulto , Preparações de Ação Retardada , Feminino , Humanos , Cinética , Carbonato de Lítio , Masculino , ComprimidosRESUMO
In a double-blind crossover placebo controlled trial the effectivity of piracetam in neuroleptic-induced extrapyramidal side effects was confirmed. 40 psychotic patients treated with neuroleptics in an average daily dose equal to 600 mg of chlorpromazine were included in this study. Akathisia, tremor, muscle rigidity and dyskinesia were evaluated on a 4-point scale. The patients were randomly divided into two subgroups--40 g of piracetam or placebo from identic ampoules were given i.v. with a crossover readministration after 60 min. The intensity of the extrapyramidal side effects was evaluated at 30-min intervals during 2 h. Piracetam was proved to be significantly effective in both subgroups, the onset of its action being between 30 and 60 min after i.v. administration. Possible interpretations of the observed piracetam effectivity are considered. Further trials with piracetam in neurologic complications during neuroleptic treatment, tardive dyskinesia included, are suggested.